Respiratorius Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Respiratorius
Access all reports
Respiratorius AB is a Swedish biotechnology company focused on developing drug candidates for the treatment of various diseases, primarily cancer, COPD (Chronic Obstructive Pulmonary Disease), and asthma. Its lead project, VAL001, is aimed at enhancing the treatment of Diffuse Large B-Cell Lymphoma (DLBCL), the most common type of aggressive lymphoma. Additionally, the company is developing substances like the RESP series, which have bronchodilating effects for respiratory conditions such as COPD and asthma. Respiratorius is also working on a cardiovascular biomarker to aid in PET imaging diagnostics. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
RESP
Country
🇸🇪 Sweden